Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 17-Oct-2018

ElectroSonix, LC


4D Acoustoelectric Cardiac Imaging (ACI), a revolutionary new modality for real-time, volumetric imaging of current flow and cardiac potentials in the heart. The proposed technology combines acoustoelectric imaging with ultrasound therapy to develop a biofeedback map. This map is generated during the ultrasound procedure and is constantly updating based on the ablations being done. This technology will be used with current ultrasound therapy to improve ablation efficacy, localization, reduce procedure time, and make the procedure safer and less invasive. Unlike most of the technology in the field, the proposed technology incorporates a bio-feedback map which is constantly updated during ablations.

Additional Questions

Who is your customer?

The typical customers are hospitals, cardiologists, neurosurgeons, and medical device manufactures.

What problem does this idea/product solve or what market need does it serve?

Recurrent cardiac arrhythmia is a serious health concern affecting more than 4 million Americans and accounts for 20% of all deaths related to heart disease. In advanced cases when drug therapy is ineffective, arrhythmias are often treated with resynchronization or ablation therapy. Intracardiac ablation procedures to correct drug-resistant arrhythmias depend on accurate maps of the cardiac activation wave. Despite global success of interventional cardiac surgery for treatment of arrhythmias, electroanatomical mapping (EAM) of the heart has significant drawbacks; for example, the slow and complex procedure is prone to image registration errors, ineffective for identifying transient arrhythmias, and has relatively poor spatial resolution (5-10 mm). With only a 50% success rate for first-time interventions, these limitations contribute to multiple erroneous ablations, repeat procedures, and increased complications for the patient. Our goal is to overcome limitations with standard electro anatomical mapping (EAM) for ablation therapy by developing 4D Acoustoelectric Cardiac Imaging (ACI), a revolutionary new modality for real-time, volumetric imaging of current flow and cardiac potentials in the heart.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Our vision is to develop the first real-time electrical cardiac mapping system based on disruptive acoustoelectric (AE) technology. Acoustoelectric imaging exploits the AE effect, an interaction between local pressure and resistivity, to remotely detect and image current densities in tissue. By combining a focused ultrasound beam with recording electrodes, ACI could achieve accurate, real-time, volumetric images of current densities in the human heart with a resolution less than 1 mm3. The patented technology will be the foundation toward product realization at ElectroSonix. Our preliminary studies suggest that ACI could offer the following benefits over EAM for localizing an arrhythmia during ablation therapy: 1) 4D electrical cardiac mapping (volume + time) at ultrasound spatial resolution (0.2-2 mm) 2) Real-time imaging for fast and accurate localization of both sustained and transient arrhythmias 3) Fusion of current densities (ACI) with cardiac anatomy and motion (pulse echo US) and blood flow (Doppler) 4) Scalable parameters (resolution, frame rate, scan area) tailored for size and type of arrhythmia 5) ACI-guided ablation therapy for real-time feedback